Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydantocidin‐5′‐phosphate is a small molecule and an experimental compound that acts as an inhibitor of adenylosuccinate synthetase. It is structurally related to purine nucleotide biosynthesis intermediates and has been studied primarily as a biochemical tool or research agent rather than for therapeutic use. Hydantocidin‐5′‐phosphate mimics the natural substrates of adenylosuccinate synthetase and binds to its active site; this enzyme catalyzes the first committed step in AMP (adenosine monophosphate) biosynthesis from IMP (inosine monophosphate). By inhibiting this enzyme’s activity—demonstrated in structural studies with Escherichia coli—the compound can disrupt purine nucleotide synthesis pathways[1][3][5]. There are no approved clinical indications or marketed products containing hydantocidin‐5′‐phosphate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydantocidin-5'-phosphate.